{"id":"https://genegraph.clinicalgenome.org/r/dc48adb0-15c6-444c-9de4-1a2138f5955cv1.0","type":"EvidenceStrengthAssertion","dc:description":"EIF2B1 related leukoencephalopathy, autosomal recessive\n\nThe *EIF2B1* gene encodes one of five subunits of eukaryotic translation initiation factor 2B (EIF2B), a GTP exchange factor for eukaryotic initiation factor 2 and an essential regulator for protein synthesis (NCBI Gene ID: 1967). *EIF2B1* was first associated with autosomal recessive leukoencephalopathy with vanishing white matter in 2002 (van der Knaap et al., PMID: 11835386). Affected individuals present with gait dysfunction, spasticity, cognitive decline, and white matter abnormalities on MRI.  Some individuals develop ovarian failure. Onset is variable from infancy to adulthood, and progression of disease is often in the setting of fever, trauma, or stress. Vanishing white matter disease has also been referred to as Childhood Ataxia with Central Nervous System Hypomyelination (CACH). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found that a phenotypic spectrum exists and there is no difference in molecular mechanism or inheritance pattern. Therefore, we chose to curate this gene-disease relationship under the disease term leukoencephalopathy with vanishing white matter 1 (OMIM:606686, MONDO:0020507). \n\nEight variants (missense, nonsense, canonical, small in-frame deletion) that have been reported in 9 probands in 8 publications (PMIDs: 11835386, 34302356, 18263758, 15776425, 32865661, 36801247, 25843247, 25761052) are included in this curation. The mechanism of pathogenicity is reported to be loss of function. This gene-disease relationship is also supported by experimental evidence. Protein interaction studies have shown that the subunit encoded by *EIF2B1* interacts with the four other EIF2B complex subunits that are encoded by genes (*EIF2B2*, *EIF2B3*, *EIF2B4*, and *EIF2B5*) definitively known to cause leukoencephalopathy with vanishing (PMID: 24532666). In summary, definitive evidence supports the relationship between *EIF2B1* and autosomal recessive leukoencephalopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Leukodystrophy and Leukoencephalopathy GCEP on the meeting date February 5, 2025 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/dc48adb0-15c6-444c-9de4-1a2138f5955c","GCISnapshot":"https://genegraph.clinicalgenome.org/r/35e2ff63-0a4f-4425-9330-cc70fbe9954d","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/35e2ff63-0a4f-4425-9330-cc70fbe9954d_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10107","date":"2025-02-05T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/35e2ff63-0a4f-4425-9330-cc70fbe9954d_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10107","date":"2025-02-12T19:51:34.551Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35e2ff63-0a4f-4425-9330-cc70fbe9954d_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b90d678e-fe42-4b99-b380-982f79a11dc7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/367abec4-1791-498d-9a6f-a093f9618da0","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/367abec4-1791-498d-9a6f-a093f9618da0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Val183Phe affects complex formation and leads to an approximately 50 % reduction in binding of this subunit to the rest of the complex (Fig. 2b).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/367abec4-1791-498d-9a6f-a093f9618da0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15776425","allele":{"id":"https://genegraph.clinicalgenome.org/r/4142146a-966a-4f47-92b2-68f36e802bef","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.547G>T (p.Val183Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347601"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/b90d678e-fe42-4b99-b380-982f79a11dc7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15776425","rdfs:label":"Ohlenbusch case 3252","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":17,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4142146a-966a-4f47-92b2-68f36e802bef"},"firstTestingMethod":"PCR","phenotypeFreeText":"Individuals were selected for analysis of eIF2B mutations according to the following MRI based criteria for VWM: 1) a symmetrically and diffusely abnormal signal of the cerebral hemispheric white matter and 2) a signal intensity of the abnormal white matter being close to that of CSF (increased signal intensity on T2-weighted, proton density or fluid-attenuated inversion recovery images and decreased signal intensity on T1-weighted images). MRI of patients 3252 and 3253 fulfilled these criteria only partially, but white matter abnormalities on MRI combined with mental retardation and ovarian failure led to the differential diagnosis of an eIF2B related disorder in these patients.","phenotypes":["obo:HP_0002352","obo:HP_0008209","obo:HP_0001249"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/367abec4-1791-498d-9a6f-a093f9618da0_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/b02bcb3f-2e5a-467a-8765-f530efcbbfe9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a57a6ff-861a-4cb5-99a9-f2f0a8c6456f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a57a6ff-861a-4cb5-99a9-f2f0a8c6456f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Tyr275Cys affects complex formation and lead to an approximately 50 % reduction in binding of this subunit to the rest of the complex (Fig. 2b).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1a57a6ff-861a-4cb5-99a9-f2f0a8c6456f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865661","allele":{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.824A>G (p.Tyr275Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347593"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0f2f3566-7276-4552-8d17-9aa55b5afb11","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f2f3566-7276-4552-8d17-9aa55b5afb11_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865661","allele":{"id":"https://genegraph.clinicalgenome.org/r/adb938d3-6c77-405c-9c92-130bced6a8fb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.439C>T (p.Arg147Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6860130"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b02bcb3f-2e5a-467a-8765-f530efcbbfe9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32865661","rdfs:label":"Pilania case","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"},{"id":"https://genegraph.clinicalgenome.org/r/adb938d3-6c77-405c-9c92-130bced6a8fb"}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0030833","obo:HP_0007185","obo:HP_0002373","obo:HP_0002352","obo:HP_0002315","obo:HP_0002183"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/1a57a6ff-861a-4cb5-99a9-f2f0a8c6456f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0f2f3566-7276-4552-8d17-9aa55b5afb11_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/a0de0ab0-30f2-454a-81d7-54938d683ebd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c284807d-79e7-4b19-b773-820ad79be54b","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c284807d-79e7-4b19-b773-820ad79be54b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25843247","allele":{"id":"https://genegraph.clinicalgenome.org/r/df44fb74-6741-414a-aeb2-d47fa2b23768","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.715T>G (p.Phe239Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347597"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/a0de0ab0-30f2-454a-81d7-54938d683ebd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25843247","rdfs:label":"Shimada case 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":29,"allele":{"id":"https://genegraph.clinicalgenome.org/r/df44fb74-6741-414a-aeb2-d47fa2b23768"},"firstTestingMethod":"PCR","phenotypeFreeText":"Cranial computed tomography showed diffusely distributed low-absorption in the white matter (no more detailed information). Her neurological deterioration progressed, and she is now bedridden.","phenotypes":["obo:HP_0001288","obo:HP_0002311","obo:HP_0003431","obo:HP_0002415","obo:HP_0001257","obo:HP_0001250"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c284807d-79e7-4b19-b773-820ad79be54b_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/df021e6b-4acb-4afc-94f1-605865cc2744_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de3f11c8-a79d-4f18-a91a-960b21d5d92f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de3f11c8-a79d-4f18-a91a-960b21d5d92f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":" Tyr275Cys affects complex formation. Tyr275Cys lead to an approximately 50% reduction in binding of this subunit to the rest of the complex.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/de3f11c8-a79d-4f18-a91a-960b21d5d92f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34302356","allele":{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7d83071e-89ff-45a1-8936-9d8005787ed4","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d83071e-89ff-45a1-8936-9d8005787ed4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34302356","allele":{"id":"https://genegraph.clinicalgenome.org/r/adb938d3-6c77-405c-9c92-130bced6a8fb"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/df021e6b-4acb-4afc-94f1-605865cc2744","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34302356","rdfs:label":"Kaur case P46","ageType":"AgeAtReport","ageUnit":"Months","ageValue":54,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/adb938d3-6c77-405c-9c92-130bced6a8fb"},{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"}],"detectionMethod":"Singleton WES.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"White matter abnormalities in periventricular white matter, corpus callosum, internal capsule and brainstem, T2W hypeintensities in basal ganglia.","phenotypes":["obo:HP_0002518","obo:HP_0012501","obo:HP_0012751"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/7d83071e-89ff-45a1-8936-9d8005787ed4_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/de3f11c8-a79d-4f18-a91a-960b21d5d92f_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/de679325-2636-4979-869e-7380bbbc71c9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a492da42-77c4-4c72-8c99-f0fe0e121bd8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a492da42-77c4-4c72-8c99-f0fe0e121bd8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Tyr275Cys affects complex formation and lead to an approximately 50 % reduction in binding of this subunit to the rest of the complex (Fig. 2b).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a492da42-77c4-4c72-8c99-f0fe0e121bd8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36801247","allele":{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c90a82ad-55f9-45de-821a-9b3b7a3e6b0d","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c90a82ad-55f9-45de-821a-9b3b7a3e6b0d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36801247","allele":{"id":"https://genegraph.clinicalgenome.org/r/adb938d3-6c77-405c-9c92-130bced6a8fb"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/de679325-2636-4979-869e-7380bbbc71c9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36801247","rdfs:label":"Chand case NCGM211","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"},{"id":"https://genegraph.clinicalgenome.org/r/adb938d3-6c77-405c-9c92-130bced6a8fb"}],"detectionMethod":"Singleton.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002373","obo:HP_0001257","obo:HP_0002064","obo:HP_0002415"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/c90a82ad-55f9-45de-821a-9b3b7a3e6b0d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a492da42-77c4-4c72-8c99-f0fe0e121bd8_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/6fa14003-4016-4727-a710-769ac2e60af9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21ea25b7-4d20-489d-b3ac-040c61e1b07f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21ea25b7-4d20-489d-b3ac-040c61e1b07f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Gly204Δ affects complex formation and is unable to interact with any of the other subunits of the eIF2B complex (Fig 2b.)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/21ea25b7-4d20-489d-b3ac-040c61e1b07f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18263758","allele":{"id":"https://genegraph.clinicalgenome.org/r/fe9432ce-6687-4669-ae6c-db52c2d779bb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.613_615del (p.Gly205del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347591"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/39d1d8ac-562c-4c37-a8a5-b3eb816d7092","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/39d1d8ac-562c-4c37-a8a5-b3eb816d7092_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":" Tyr275Cys affects complex formation. Tyr275Cys lead to an approximately 50% reduction in binding of this subunit to the rest of the complex.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/39d1d8ac-562c-4c37-a8a5-b3eb816d7092_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18263758","allele":{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6fa14003-4016-4727-a710-769ac2e60af9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18263758","rdfs:label":"Maletkovic case","allele":[{"id":"https://genegraph.clinicalgenome.org/r/fe9432ce-6687-4669-ae6c-db52c2d779bb"},{"id":"https://genegraph.clinicalgenome.org/r/4e6bb539-b6c9-4824-8fe0-662ac7b8c070"}],"detectionMethod":"Both strands of the resulting PCR products were sequenced using an ABI 3130® automated sequencer (Applied Biosystems).","firstTestingMethod":"PCR","phenotypeFreeText":"Patients were included in the study if they fulfilled the following minimum criteria:\n(1) MRI findings suggestive of eIF2B-related disorders, (2) normal karyotype, (3) no evidence of underlying inborn error of metabolism on available screening. Patient’s clinical history and physical findings by report of the referring physician were reviewed in a standardized manner. All MRI images were reviewed by both A.V. and N.K.\n","phenotypes":"obo:HP_0002415","previousTesting":true,"previousTestingDescription":"Karyotype","secondTestingMethod":"Other","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/39d1d8ac-562c-4c37-a8a5-b3eb816d7092_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/21ea25b7-4d20-489d-b3ac-040c61e1b07f_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/617f73db-ca86-4007-8edb-2714733fb791_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e759d131-6a2a-48fa-8d89-f472fa7b84ed","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e759d131-6a2a-48fa-8d89-f472fa7b84ed_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Val183Phe affects complex formation and leads to an approximately 50 % reduction in binding of this subunit to the rest of the complex (Fig. 2b).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e759d131-6a2a-48fa-8d89-f472fa7b84ed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15776425","allele":{"id":"https://genegraph.clinicalgenome.org/r/4142146a-966a-4f47-92b2-68f36e802bef"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/617f73db-ca86-4007-8edb-2714733fb791","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15776425","rdfs:label":"Ohlenbusch case 3253","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4142146a-966a-4f47-92b2-68f36e802bef"},"firstTestingMethod":"PCR","phenotypeFreeText":"Individuals were selected for analysis of eIF2B mutations according to the following MRI based criteria for VWM: 1) a symmetrically and diffusely abnormal signal of the cerebral hemispheric white matter and 2) a signal intensity of the abnormal white matter being close to that of CSF (increased signal intensity on T2-weighted, proton density or fluid-attenuated inversion recovery images and decreased signal intensity on T1-weighted images). MRI of patients 3252 and 3253 fulfilled these criteria only partially, but white matter abnormalities on MRI combined with mental retardation and ovarian failure led to the differential diagnosis of an eIF2B related disorder in these patients.","phenotypes":["obo:HP_0001249","obo:HP_0008209","obo:HP_0002352"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e759d131-6a2a-48fa-8d89-f472fa7b84ed_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/506f07a4-c449-4809-8af6-ea42e6f5184e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0cbfc459-4f0a-4b16-8e0a-adfef8782420","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0cbfc459-4f0a-4b16-8e0a-adfef8782420_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Asn208Tyr has been previously described as destabilising eIF2Bα when overexpressed in yeast cells (Richardson et al.; PMID: 14993275). Wortham & Proud analysed expression of subunits by western blotting (Fig. 2a). They did not find consistent destabilisation caused by Asn208Tyr (PMID: 26285592). They propose the discrepancy is likely due to differences between yeast and mammals.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/0cbfc459-4f0a-4b16-8e0a-adfef8782420_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11835386","allele":{"id":"https://genegraph.clinicalgenome.org/r/5bc617f9-0da6-4771-89f2-0c7ba291499a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.622A>T (p.Asn208Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340166"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/29347314-4a74-4a3e-8ca2-3492f5126caa","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29347314-4a74-4a3e-8ca2-3492f5126caa_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11835386","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d02111a-a041-4621-b94f-150d92faf606","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.252+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340165"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/506f07a4-c449-4809-8af6-ea42e6f5184e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11835386","rdfs:label":"van der Knaap case vwm217","allele":[{"id":"https://genegraph.clinicalgenome.org/r/8d02111a-a041-4621-b94f-150d92faf606"},{"id":"https://genegraph.clinicalgenome.org/r/5bc617f9-0da6-4771-89f2-0c7ba291499a"}],"firstTestingMethod":"PCR","phenotypeFreeText":"The patients fulfilled the same MRI criteria as the patients in whom mutations had been found in EIF2B5 and EIF2B2 (Fig 1): (1) the cerebral hemi- spheric white matter is symmetrically and diffusely abnormal; (2) part or all of the abnormal white matter has a signal intensity close to or the same as CSF on both T2-weighted and either proton density or fluid-attenuated inversion recovery (FLAIR) images; (3) a fine meshwork of remaining tissue strands is visible within the areas of CSF-like white matter, with a typical radiating appearance on sagittal and coronal images and a dotlike pattern in the centrum semiovale on the transverse images.","phenotypes":"obo:HP_0002415","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/29347314-4a74-4a3e-8ca2-3492f5126caa_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/0cbfc459-4f0a-4b16-8e0a-adfef8782420_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/aad311d5-6bfe-48bc-824b-690b8216bdad_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/26ebfa5f-4c84-436f-bec8-2d4005fce786","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/26ebfa5f-4c84-436f-bec8-2d4005fce786_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25761052","allele":{"id":"https://genegraph.clinicalgenome.org/r/8f1b9518-20a2-4229-95e3-8449000f7742","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001414.4(EIF2B1):c.328A>G (p.Lys110Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA347599"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/aad311d5-6bfe-48bc-824b-690b8216bdad","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25761052","rdfs:label":"Zhang case 29","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":26,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8f1b9518-20a2-4229-95e3-8449000f7742"},"detectionMethod":"\"Gene sequencing\"","firstTestingMethod":"Other","phenotypeFreeText":"Episodic aggravation. \n\nThe clinical diagnosis of early childhood VWM (onset age 2–6years) is mainly on the basis of the following criteria [14]. 1) Early psychomotor development is usually normal or mildly de-\nlayed; 2) The clinical presentation consists of early-childhood onset of episodic and chronically progressive neurological regression. Episodes of rapid deterioration might be provoked by mild head trauma, febrile infection or fear; 3) Neurological signs mainly consist of cerebellar ataxia and spasticity; and 4) The brain MRI shows diffuse and symmetrical signal in cerebral white matter similar to cerebrospinal fluid on T1-weighted, T2-weighted and flair images (Fig. 1).","phenotypes":["obo:HP_0002540","obo:HP_0001250","obo:HP_0002415"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/26ebfa5f-4c84-436f-bec8-2d4005fce786_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11},{"id":"https://genegraph.clinicalgenome.org/r/35e2ff63-0a4f-4425-9330-cc70fbe9954d_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35e2ff63-0a4f-4425-9330-cc70fbe9954d_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5e1df5b-f55c-44f0-ade2-9408b630c292","type":"EvidenceLine","dc:description":"Per GCEP, points upgraded from 0.5 to 1 given EIF2B1 interacts with multiple vanishing white matter genes.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/478c7500-353f-47f4-8494-ff0bad01018e","type":"Finding","dc:description":"eIF2B is a decameric, a dimer of eIF2B (beta, gamma, delta, epsilon) tetramers stabilized by 2 copies of eIF2Bα. EIF2B1 is experimentally proven to interact with EIF2B2, EIF2B3, EIF2B4, and EIF2B5, which have been established to cause vanishing white matter disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24532666","rdfs:label":"Protein Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Definitive","sequence":9961,"specifiedBy":"GeneValidityCriteria11","strengthScore":12,"subject":{"id":"https://genegraph.clinicalgenome.org/r/KAtePvVgCQ4","type":"GeneValidityProposition","disease":"obo:MONDO_0020507","gene":"hgnc:3257","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_35e2ff63-0a4f-4425-9330-cc70fbe9954d-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}